Clinical Research Details

Back to List
Descriptive Information
Exosomal microRNAs in Multiple Sclerosis: Reconciling expression signatures with disease relapse, remission, and response to treatment

Samia Khoury
sk88@aub.edu.lb

IM.SK1.03
Completed

Clinical Research - Mechanisms of Human Disease  


No
Conditions and Keywords
Multiple Sclerosis
Multiple Sclerosis
Study Design
Other: Describe in Detailed Description
To assess Ex-miRNA expression patterns during different disease stages of MS and whether that pattern is modified by therapy. To assess the effect of relapse on the expression profile of Ex-miRNA.
N/A: Not Applicable
Prospective
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
Case Control
Eligibility and IRB
Both
Min: 18
Max: 65
Yes
Yes

Blood will be sampled before starting treatment and at 3, 6, 9, and 12 months after starting treatment from newly diagnosed untreated patients along with patients who stopped treatment for 3- 6 months (before study). Participants in the control group will have their blood only drawn once. Patients will also have clinical assessment (including Expanded Disability Scale Scores (EDSS)) at each visit and MRI scans as clinically indicated (at time 0 and 12 months).

Multiple Sclerosis patients visiting the MS Center

Age and gender-matched healthy controls

Non-probability sampling

- Definite MS by McDonald criteria; Relapsing-remitting disease (RRMS) about to be started on interferon-β, secondary progressive disease (SPMS) about to be started on cyclophosphamide therapy, or RRMS on treatment but experiencing an acute exacerbation.
- Healthy adult subjects who are not known to have an autoimmune disease.


Back to List